Figure 5.

Bc-NFκBdODN Induces Immune-Mediated Tumor Regression

A20 cells were injected subcutaneously in both flanks of BALB/c mice. After tumors were established (days 9–13), tumors on one side were treated every other day with 1 mg/kg Bc-NFκBdODN for 2 weeks while tumors on the other side were left untreated. (A) Tumor progression was analyzed using caliper measurements. Shown are combined data from two independent experiments (means ± SEM; n = 9 in each group). (B–E) The percentage of CD11b⁺Gr1⁺ immature myeloid cells (B) and PD-L1 expression (C), together with percentages of tumor-infiltrating CD3⁺ and CD8⁺ T cells (D) and PD-1 expression (E), were analyzed in cell suspensions from the untreated/distant tumors. Shown are representative flow cytometry histograms (means ± SEM; n = 6/group). (F) Mice were injected with 200 μg of CD8 depleting antibodies on day 6 after tumor engraftment. Three days later, mice were injected 1 mg/kg Bc-NFκBdODN intratumorally every other day three times. Means ± SEM are shown (n = 5/group).